A Study of Once-Daily Oral Orforglipron (LY3502970) in Japanese Adult Participants With Obesity Disease

PHASE3CompletedINTERVENTIONAL
Enrollment

238

Participants

Timeline

Start Date

July 31, 2023

Primary Completion Date

June 19, 2025

Study Completion Date

June 19, 2025

Conditions
Obesity
Interventions
DRUG

Orforglipron

Administered orally

DRUG

Placebo

Administered orally

Trial Locations (16)

311-0133

Nishiyamadou Keiwa Hospital, Naka

300-0062

Tsuchiura Beryl Clinic, Tsuchiura

300-0835

Ohishi Internal Medicine Clinic, Tsuchiura

247-0055

Shonan Takai Clinic, Kamakura

247-0056

Takai Internal Medicine Clinic, Kamakura-shi

252-0302

Medical Corporation Yuga Higashirinkan Kaneshiro Diabetes Clinic, Sagamihara

582-0005

Shiraiwa Medical Clinic, Kashihara

565-0853

Medical Corporation Heishinkai OCROM Clinic, Suita-shi

332-0012

Sugiura Clinic, Kawaguchi

102-0084

Yotsuya Medical Cube, Chiyoda City

103-0025

Nihonbashi Sakura Clinic, Chuo-ku

103-0027

Tokyo-Eki Center-building Clinic, Chuo-ku

104-0031

Fukuwa Clinic, Chuo-ku

160-0008

Heishinkai Medical Group ToCROM Clinic, Shinjuku-ku

732-0053

Hiroshima Station Clinic, Hiroshima

530-0001

Osaka Nishiumeda Clinic, Osaka

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY